Abstract

Introduction . Drug encapsulation efficiency (EE) is the important parameter of the nanoparticle-based drug formulations. Generally, the methods for evaluation of the EE are based on separation of the free and NP-bound fractions of the drug; however, applicability of these methods for a particulate formulation needs careful consideration. Aim. The purpose of the study was to optimize the procedure for evaluation of the EE for a nanoparticle-based drug formulation taking doxorubicin loaded in the PLGA nanoparticles (PLGA-Dox NP) as a model formulation. Materials and methods. The PLGA-Dox NP were prepared by a “double emulsion” method at pH of the external aqueous phase of 7.4 or 6.4. The NP size and size distribution (PDI) were determined by photon correlation spectroscopy (PCS) and transmission electron microscopy (TEM). For the EE evaluation of doxorubicin, the NP were separated by centrifugation (CF), ultrafiltration (UF), or gel filtration. The efficiency of NP separation by the CF method was evaluated by the PLGA content in the supernatant by capillary electrophoresis (CZE). Results and discussion. The average hydrodynamic diameter of the PLGA-Dox/7.4 and PLGA-Dox/6.4 NP (FCS) was 103 ± 10 nm and 141 ± 8 nm, respectively. According to the TEM data, the main fraction of the NP averaged 50 ± 16 nm. The EE of doxorubicin, determined after the NP separation by centrifugation at 48254.g, was 78.9 ± 1.8 % for the PLGA-Dox/6.4 and 91.5 ± 0.9 % for the PLGA-Dox/7.4 NP with the residual PLGA content in the supernatant of ~5 %. At lower acceleration the NP separation was incomplete leading to underestimation of the EE. Also, the ultrafiltration method using the filters with the NMWL of 50 and 100 kDa enabled the reliable NP separation with the minimal doxorubicin adsorption on the filter (<4 %). Separation of the NP by gel filtration led to the underestimation of the EE due to considerable desorption of doxorubicin from the NP surface. Conclusion. The optimal analytical procedures for evaluation of the EE of doxorubicin in the PLGA NP are based on the NP separation by CF at 48254×g and UF using filters with NMWL of 50 and 100 kDa.

Highlights

  • Drug encapsulation efficiency (EE) is the important parameter of the nanoparticle-based drug formulations

  • The purpose of the study was to optimize the procedure for evaluation of the EE for a nanoparticle-based drug formulation taking doxorubicin loaded in the poly(lactic-co-glycolic acid) (PLGA) nanoparticles (PLGA-Dox NP) as a model formulation

  • The PLGA-Dox NP were prepared by a «double emulsion» method at pH of the external aqueous phase of 7.4 or 6.4

Read more

Summary

МАТЕРИАЛЫ И МЕТОДЫ

Наночастицы PLGA, нагруженные доксорубицином (PLGA-Dox НЧ), получали методом «двойных эмульсий» (W1/O/W2), как описано в опубликованных ранее работах авторов [5]. Первичную эмульсию (W1/O) получали путем эмульгирования внутренней водной фазы (W1), представляющей собой раствор доксорубицина гидрохлорида (Yick-Vic Chemicals & Pharmaceuticals, Hong Kong, China) в 0,001 н соляной кислоте, с раствором PLGA (Resomer® 502H, D,L-лактид/гликолид = 50:50 моль/моль; молекулярная масса 7–17 кДа, Evonik Nutrition & Care GmbH, Германия) в дихлорметане (х.ч., Химмед, Россия) при помощи гомогенизатора (Ultra-Turrax T 18 Basic, IKA, Германия) в течение 1 минуты при 23600 об/мин. Содержание полимера в PLGA-Dox определяли методом капиллярного электрофореза (КЭФ, Капель-105M, Lumex, Россия) с программным обеспечением Elforun® (Lumex, Россия), как описано в [6]. Общее содержание доксорубицина в PLGA-Dox НЧ определяли спектрофотометрически (Shimadzu UV-1800, Япония) при λmax = 480 нм после растворения лиофилизата НЧ в ДМСО (0,00–50 мкг/мл; r = 0,9995). Степень включения доксорубицина в PLGA-Dox НЧ оценивали путем отделения фракции НЧ от свободного доксорубицина методами центрифугирования, ультрафильтрации и гель-фильтрации

Метод центрифугирования
Метод ультрафильтрации
Статистический анализ данных
РЕЗУЛЬТАТЫ И ИХ ОБСУЖДЕНИЕ
Findings
Тип НЧ
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.